Aditx Therapeutics Inc Stock

$0.47

6.04% day before yesterday

Nasdaq, Sep 06, 10:17 pm CET

ISIN

US0070251097

Symbol

ADTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Aditx Therapeutics Inc Stock price

$0.47

-10,119.53 100.00% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

+0.03 6.04%

ISIN

US0070251097

Symbol

ADTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$1.68m
Enterprise Value	$9.41m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	28.52
P/S ratio (TTM) P/S ratio	5.09
P/B ratio (TTM) P/B ratio	0.14
Revenue growth (TTM) Revenue growth	-65.22%
Revenue (TTM) Revenue	$330.00k
EBIT (operating result TTM) EBIT	$-33.56m
Free Cash Flow (TTM) Free Cash Flow	$-19.60m
Cash position	$90.00k
EPS (TTM) EPS	$-70.54
P/E forward	0.00
P/S forward	1.07
EV/Sales forward	6.31
Short interest	20.59%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Aditx Therapeutics Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Aditx Therapeutics Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	0.33 0.33	65% 65% 100%
- Direct Costs	1.05 1.05	21% 21% 318%
Gross Profit	-0.72 -0.72	89% 89% -218%
- Selling and Administrative Expenses	17 17	11% 11% 5,261%
- Research and Development Expense	15 15	129% 129% 4,515%
EBITDA	-33 -33	47% 47% -9,997%
- Depreciation and Amortization	0.57 0.57	2% 2% 173%
EBIT (Operating Income) EBIT	-34 -34	45% 45% -10,169%
Net Profit	-43 -43	57% 57% -13,027%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aditx Therapeutics Inc Stock News

Neutral

Business Wire

●

9 days ago

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York ...

Neutral

Business Wire

●

12 days ago

Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagn...

Neutral

PRNewsWire

●

18 days ago

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management ...

More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office	United States
CEO	Amro Albanna
Employees	47
Founded	2017
Website	www.aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now